author-photo

Anitra Fielding

AstraZeneca

48

Papers

3550

Citations

Citation Trend

Filter By

Papers (30) Sort By

Journal Conference Others

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.

2021 The New England Journal of Medicine
Show All
- Source
- Cite
- Save
Citations (61)
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment

2019 Clinical Pharmacokinectics
Show All
- Source
- Cite
- Save
Citations (6)
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy

2018 British Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (81)
950POlaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy

2018 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting

2017 Oncotarget
Show All
- Source
- Cite
- Save
Citations (56)
Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (18)
PHARMACOKINETICS AND SAFETY OF OLAPARIB IN PATIENTS WITH ADVANCED SOLID TUMORS AND HEPATIC OR RENAL IMPAIRMENT

2017 Clinical Pharmacology & Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
LBA42Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (1)
An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib

2016 Targeted Oncology
Show All
- Source
- Cite
- Save
Citations (74)
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-Label Studies.

2016 Clinical Therapeutics
Show All
- Source
- Cite
- Save
Citations (23)